|Report Code: PP10267||Published: July 2019||Pages: 300+||Available format:|
|Therapeutic Area(s):||Oncology||Report Type: Indication Pipeline Reports|
Rectal cancer refers to formation of malignant cells inside the rectum. This type of cancer develops over several years, first growing as a polyp, which is precancerous growth. Whereas, some polyps can turn into cancer. There are some common symptoms of the cancer such as diarrhea, constipation, dark or red blood in stool, mucus in stool, abdominal pain, and iron deficiency. Though the exact reason of the cancer in not known, but it is expected that mutations in DNA of rectal cells lead to the cancer. Rectal cancer can also be inherited, such as hereditary nonpolyposis colorectal cancer (HNPCC), which is developed before age of 50 years, and familial adenomatous polyposis (FAP), which is developed before age of 40 years.
Moreover, some risk factors of the disease include family or personal history of rectal cancer, excessive alcohol consumption, smoking, and obese. It can be diagnosed by physical examination, colonoscopy, digital rectal examination, carcinoembryonic antigen (CEA) assay, and biopsy. Additionally, colonoscopy and chest X-rays help in identifying stage of the cancer.
Opdivo (Bristol-Myers Squibb Company), Avastin (Genentech Inc.), and Erbitux (Eli Lilly and Company) are some of the drugs approved by the Food and Drug Administration (FDA) for the treatment of rectal cancer.
Positive clinical trial results and adoption of collaboration strategies are enhancing rectal cancer therapeutics pipeline. Moreover, the issuance of patents helps in achieving different milestones in the form of grants and designations from regulatory bodies and institutes, including the U.S. Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the National Institutes of Health (NIH).
As of March 2019, the rectal cancer therapeutics pipeline comprised 10+ drugs in different stages of development.
The report provides epidemiology forecast of rectal cancer for seven major markets, such as the U.S., Japan, and EU5 countries (the U.K., Germany, France, Italy, and Spain). It covers prevalent population and treated patient population for the period 2016–2028. According to GLOBOCAN-2018 statistics, there were 155,098 new cases of rectal cancer in the U.S.
Some of the key players involved in the development of rectal cancer therapeutics are Eli Lilly and Company, Taiwan Liposome Company Ltd., Genentech Inc., Sanofi-aventis Groupe, Merck & Co. Inc., Bristol-Myers Squibb Company, Hutchison MediPharma, Seattle Genetics Inc., and Advaxis Inc.
Some highlights of the report “Rectal Cancer Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” have been mentioned below: